PhosImmune Inc. is developing cancer vaccines based on a class of aberrantly phosphorylated antigens that are directly involved in cellular transformation and/or metastasis. The company expects its vaccines to be more specific and potent than vaccines that use antigens derived from proteins that are overexpressed in cancers but are not the root cause of the tumor.

In addition, PhosImmune is able to select antigens that bind tightly to major histocompatibility complex class I (MHC I) and elicit a robust memory T cell response against the tumor - something the company says traditional cancer vaccines have been unable to do.